The Fort Worth Press - Wellgistics Health Reports 36% Revenue Growth in Q1 2025 as Manufacturer Access and Pharmacy Onboarding Accelerate

USD -
AED 3.673042
AFN 65.000368
ALL 81.855041
AMD 360.540403
ANG 1.790403
AOA 918.000367
ARS 1546.131265
AUD 1.476887
AWG 1.8
AZN 1.70397
BAM 1.769883
BBD 2.014669
BDT 124.411223
BGN 1.77347
BHD 0.37715
BIF 3005
BMD 1
BND 1.287984
BOB 11.678099
BRL 5.666304
BSD 1.000231
BTN 94.214794
BWP 13.981141
BYN 2.99667
BYR 19600
BZD 2.011773
CAD 1.42715
CDF 2315.000362
CHF 0.838719
CLF 0.025287
CLP 995.220396
CNY 6.67175
CNH 6.67522
COP 3319.97
CRC 448.217041
CUC 1
CUP 24.005936
CVE 100.150394
CZK 22.139304
DJF 177.720393
DKK 6.782304
DOP 60.703884
DZD 137.227489
EGP 53.502064
ERN 15
ETB 161.050392
EUR 0.90715
FJD 2.25325
FKP 0.756884
GBP 0.75683
GEL 2.590391
GGP 0.756884
GHS 11.72504
GIP 0.756884
GMD 74.000355
GNF 8857.503848
GTQ 7.646644
GYD 209.264655
HKD 7.84565
HNL 26.950388
HRK 6.831965
HTG 131.169348
HUF 331.003504
IDR 18235.4
ILS 3.216704
IMP 0.756884
INR 94.25795
IQD 1514
IRR 1913737.503816
ISK 123.930386
JEP 0.756884
JMD 158.047862
JOD 0.70904
JPY 159.72504
KES 130.050385
KGS 87.435504
KHR 4080.00035
KMF 447.00035
KPW 900.00035
KRW 1336.565039
KWD 0.31147
KYD 0.833529
KZT 445.849094
LAK 22530.000349
LBP 89550.000349
LKR 332.687818
LRD 170.000348
LSL 16.930381
LTL 2.95274
LVL 0.60489
LYD 6.445039
MAD 9.961704
MDL 18.169149
MGA 4590.000347
MKD 55.830725
MMK 2099.848767
MNT 3604.365716
MOP 8.083632
MRU 40.603743
MUR 47.620378
MVR 15.403739
MWK 1736.000345
MXN 18.536504
MYR 4.086104
MZN 63.903729
NAD 16.930377
NGN 1343.570377
NIO 36.803722
NOK 9.57248
NPR 150.739077
NZD 1.809628
OMR 0.385141
PAB 1.000231
PEN 3.403039
PGK 4.511504
PHP 63.960375
PKR 276.603701
PLN 3.996535
PYG 6207.891986
QAR 3.64425
RON 4.851904
RSD 106.559038
RUB 82.829047
RWF 1476
SAR 3.77446
SBD 8.097697
SCR 13.945304
SDG 601.503676
SEK 10.075038
SGD 1.287204
SHP 0.752984
SLE 23.050371
SLL 20969.503664
SOS 572.503662
SRD 37.49037
STD 20697.981008
STN 22.2
SVC 8.752585
SYP 13002.000337
SZL 16.930369
THB 33.875038
TJS 9.227282
TMT 3.5
TND 3.008504
TOP 2.40776
TRY 50.342104
TTD 6.789769
TWD 32.891404
TZS 2648.920367
UAH 45.477786
UGX 4131.053487
UYU 40.541335
UZS 12039.000334
VES 912.87925
VND 25725.5
VUV 120.638016
WST 2.81058
XAF 595.051667
XAG 0.020459
XAU 0.00025782798
XCD 2.70255
XCG 1.802699
XDR 0.707052
XOF 595.051667
XPF 108.325037
YER 236.550363
ZAR 16.976255
ZMK 9001.203584
ZMW 20.450473
ZWL 321.999592
SSP 5946.454122
MXV 2.081672
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Wellgistics Health Reports 36% Revenue Growth in Q1 2025 as Manufacturer Access and Pharmacy Onboarding Accelerate
Wellgistics Health Reports 36% Revenue Growth in Q1 2025 as Manufacturer Access and Pharmacy Onboarding Accelerate

Wellgistics Health Reports 36% Revenue Growth in Q1 2025 as Manufacturer Access and Pharmacy Onboarding Accelerate

TAMPA, FL / ACCESS Newswire / May 12, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX, "Wellgistics Health"), a healthcare infrastructure and pharmaceutical distribution company leveraging proprietary technology, today announced financial results for its first fiscal quarter ended March 31, 2025.

Text size:

Revenue for the Q1 2025 quarter increased to $10.86 million from zero during the comparable period last year on a GAAP basis. Had the Company acquired Wood Sage and Wellgistics LLC as of January 1, 2024, the $10.86 revenue figure of Q1 2025 would be compared to $7.97 million on a pro forma basis for the same period in 2024, representing approximately a 36% year-over-year increase on a non-GAAP basis.

"Our Q1 growth reflects the momentum we are building across every part of the business," said Brian Norton, CEO of Wellgistics Health. "We're expanding our manufacturer relationships, broadening our product portfolio, and registered 354 new pharmacies this quarter-nearly two-thirds of which have already placed at least one order. We're also laying the groundwork for the next phase of scale with new hub service capabilities and technology infrastructure, including the upcoming expansion of our Peek platform."

"Since the IPO in March, Brian has moved with speed and precision to reshape Wellgistics Health into a modern, execution-driven healthcare platform," said Suren Ajjarapu, Chairman of the Board. "He has rebuilt the executive team into one of the most capable leadership groups in the industry and supercharged every aspect of the business-from commercial operations to pharmacy expansion to manufacturer access. This quarter's results are an early indication of what's possible. While we have structured financial tools like the ELOC to support strategic acceleration, we are committed to deploying capital only when it directly fuels outsized growth and market share expansion."

Wellgistics Health expects continued momentum in Q2, supported by expanded clinical fulfillment capacity, new manufacturer integrations, and scaled deployment of its pharmacy hub platform.

About Wellgistics Health

Wellgistics Health, Inc. is a publicly traded healthcare infrastructure company redefining how medications move, are priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a nationwide network of over 6,000 independent pharmacies.

Wellgistics Health provides real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment solutions, while equipping pharmacies with integrated financial, clinical, and digital tools. Its end-to-end platform supports a broad range of therapeutic areas from specialty-lite to chronic maintenance medications by eliminating friction, accelerating reimbursements, and enabling direct, transparent connections between manufacturers, providers, pharmacies, and patients.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans, including without limitation its plan in connection with certain financings and cryptocurrencies and outlook and actions with respect to incurring future expenses. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov.

Note on Non-GAAP Financial Measures

Certain of the information set forth herein, including revenue on a pro forma basis, may be considered financial measures that are not recognized under United States generally accepted accounting principles, or non-GAAP financial measures. These measures may not be comparable to similar measures presented by other companies. Wellgistics Health defines revenue on a pro forma basis to include revenues as adjusted based on the assumption that Wellgistics Health acquired its two direct subsidiaries, Wood Sage, LLC and Wellgistics, LLC, on January 1, 2024.

Wellgistics Health believes this financial information is useful to investors as a measure of profitability, because it helps us compare our performance on a consistent basis by removing from our operating results the impact of our capital structure, the effect of operating in different tax jurisdictions, the impact of our asset base, which can differ depending on the book value of assets and the accounting methods used to compute depreciation and amortization, and the cost of acquiring businesses and restructuring our operations. In addition, the company's management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measures in evaluating the company's operating performance and cash flow. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures as reported by the company may not be comparable to similarly titled amounts reported by other companies.

For more information, please contact:

Media Contact: [email protected]
Investor Relations: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

H.M.Hernandez--TFWP